[A21-98] Cemiplimab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V
Last updated 02.11.2021
Project no.:
A21-98
Commission:
Commission awarded on 21.07.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
First-line treatment of adult patients with non-small cell lung cancer (NSCLC) whose tumours express programmed cell death ligand 1 (PD-L1) in ≥ 50% of the tumour cells and have no aberrations due to epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) or C-ros oncogene 1 (ROS1)
Treatment is intended for patients with locally advanced NSCLC who are not candidates for definitive radiochemotherapy or patients with metastatic NSCLC
Added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A21-97 | Cemiplimab (basal cell carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A19-60 | Cemiplimab - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-37 | Cemiplimab (NSCLC, combination with platin-based chemotherapy) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-36 | Cemiplimab (cervical cancer) – Benefit assessment according to §35a Social Code Book V | Commission completed |